Forex Expo Dubai 2025 Nears Sell-Out as Over 250 Global Brands Confirm Participation
From its debut in 2019 with just 50 exhibiting companies, Forex Expo Dubai has experienced phenomenal growth, transforming into one of the world's most influential forex & trading events. Today, it stands as one of the largest forex gatherings globally, offering brands the opportunity to drive real business outcomes through high-impact engagement and expanded visibility across priority trading markets worldwide.
Top-tier participants already confirmed for this year's edition include ADSS, Alpari, CFI Financial Group, CXM, Eightcap, Exness, IC Markets, Ingot, JustMarkets, Kanak Capital Markets, Traze, Valetax, Vantage, VT Markets, xChief, XM, XS.com, among others— reinforcing the event's credibility and continued upward trajectory.
With a surge in space requirements driven by strong demand from key industry players, the 2025 edition of Forex Expo Dubai is now entering its final phase of stand confirmations.
'Each year, we witness a surge in demand as leading global players recognize the tangible business value and networking reach that Forex Expo Dubai delivers. With booth space running out, we're entering the final phase of confirmations for companies serious about growth and visibility in the region.'
Global Industry Representation: The 2025 edition will feature over 250 exhibiting companies from more than 30 countries, showcasing next-generation trading platforms, liquidity solutions, and financial technologies.
Targeted Audience: Forex Expo Dubai is expected to welcome over 30,000 traders, investors, fund managers, introducing brokers (IBs), and affiliates — delivering highly focused exposure for participating brands.
Premium Content: The conference agenda includes 100+ expert speakers, featuring regulatory leaders, market analysts, and fintech pioneers shaping the future of global finance.
Onsite Business Generation: Proven across past editions, exhibitors consistently close high-value partnerships and client deals through one-on-one meetings and live product demonstrations held directly on the expo floor.
Direct Engagement with Retail Traders: The event attracts a massive retail trading community actively seeking new platforms, tools, and broker relationships — providing an ideal environment for exhibitors to convert footfall into long-term customers.
A Few Spaces Remain for Brands Still Looking to Participate
With strong demand and most of the floor now committed, a limited number of spaces remain available for industry players looking to align with the global forex community in Dubai. Leading brands still have the opportunity to join this year's edition and benefit from strategic visibility, high-impact engagement, and direct access to key decision-makers.
For exhibitor inquiries or to request the latest floorplan, interested parties may contact sales@hqmena.com, visit https://theforexexpo.com/dubai, or call/WhatsApp the organizing team at +971 50 605 1205.
About Forex Expo Dubai
Forex Expo Dubai is the region's leading event for traders, brokers, fintech innovators, and financial institutions. Organized by HQ MENA, the expo is held annually at the Dubai World Trade Centre and brings together the global forex and trading community for two days of high-impact networking, product showcases, and expert-led conference sessions.
HQ MENA is a leading event organizer based in the UAE, focused on delivering world-class exhibitions and conferences across fintech, crypto, finance, and online trading. Its mission is to connect global companies with high-intent audiences through content-rich, high-energy event experiences that drive real results.
Contact
Commercial Director
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
RECKITT BENCKISER 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Reckitt Benckiser Group PLC
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until to file lead plaintiff applications in a securities class action lawsuit against Reckitt Benckiser Group PLC ('Reckitt' or the 'Company') (OTC: RBGLY), if they purchased the Company's American Depositary Shares ('ADSs') between January 13, 2021 and July 28, 2024, inclusive (the 'Class Period'). This action is pending in the United States District Court for the Southern District of New York. What You May Do If you purchased ADSs of Reckitt and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( or visit to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by August 4, 2025. About the Lawsuit Reckitt and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) preterm infants were at an increased risk of developing necrotizing enterocolitis ('NEC') by consuming the Company's cow's milk-based formula, Enfamil; (ii) such risk could impact the Company's sales of Enfamil and expose the Company to legal claims; and (iii) as a result of the foregoing, the Company's positive statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The case is Elevator Constructors Union Local No. 1 Annuity & 401(K) Fund v. Reckitt Benckiser Group PLC, et al., No. 25-cv-4708. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit
Hamilton Spectator
3 days ago
- Hamilton Spectator
Shell plc Second Quarter 2025 Interim Dividend
London, July 31, 2025 − The Board of Shell plc (the 'Company') (XLON: SHEL, XNYS: SHEL, XAMS: SHELL) today announced an interim dividend in respect of the second quarter of 2025 of US$ 0.358 per ordinary share. Details relating to the second quarter 2025 interim dividend Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling. An alternative 'Electronic Election Entitlement' ('EEE') process is available in CREST for dividends with options elections. Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros. Absent any valid election to the contrary, shareholders (both holding in certificated and uncertificated form (CREST members)) and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling. The pound sterling and euro equivalent dividend payments will be announced on September 8, 2025. Cash dividends on American Depositary Shares ('ADSs') will be paid, by default, in US dollars. Each ADS represents two ordinary shares. ADSs are evidenced by an American Depositary Receipt ('ADR') certificate. In many cases the terms ADR and ADS are used interchangeably. Dividend timetable for the second quarter 2025 interim dividend Note A different currency election date may apply to shareholders holding shares in a securities account with a bank or financial institution ultimately holding through Euroclear Nederland. This may also apply to other shareholders who do not hold their shares either directly on the Register of Members or in the corporate sponsored nominee arrangement. Shareholders can contact their broker, financial intermediary, bank or financial institution for the election deadline that applies. Taxation - cash dividends If you are uncertain as to the tax treatment of any dividends you should consult your tax advisor. Dividend Reinvestment Programmes ('DRIP') The following organisations offer Dividend Reinvestment Plans ('DRIPs') which enable the Company's shareholders to elect to have their dividend payments used to purchase the Company's shares: These DRIP offerors provide their DRIPs fully on their account and not on behalf of the Company. Interested parties should contact the relevant DRIP offeror directly. More information can be found at To be eligible to participate in the DRIPs for the next dividend, shareholders must make a valid dividend reinvestment election before the published date for the close of elections. Enquiries Media: International +44 (0) 207 934 5550; U.S. and Canada: Cautionary Note The companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement 'Shell', 'Shell Group' and 'Group' are sometimes used for convenience to reference Shell plc and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. ''Subsidiaries'', 'Shell subsidiaries' and 'Shell companies' as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. The terms 'joint venture', 'joint operations', 'joint arrangements', and 'associates' may also be used to refer to a commercial arrangement in which Shell has a direct or indirect ownership interest with one or more parties. The term 'Shell interest' is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement, after exclusion of all third-party interest. Forward-Looking statements This announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition, results of operations and businesses of Shell. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include, among other things, statements concerning the potential exposure of Shell to market risks and statements expressing management's expectations, beliefs, estimates, forecasts, projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as 'aim'; 'ambition'; ''anticipate''; 'aspire'; 'aspiration'; ''believe''; 'commit'; 'commitment'; ''could''; 'desire'; ''estimate''; ''expect''; ''goals''; ''intend''; ''may''; 'milestones'; ''objectives''; ''outlook''; ''plan''; ''probably''; ''project''; ''risks''; 'schedule'; ''seek''; ''should''; ''target''; 'vision'; ''will''; 'would' and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement, including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shell's products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks, including climate change; (h) risks associated with the identification of suitable potential acquisition properties and targets, and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative, judicial, fiscal and regulatory developments including tariffs and regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks, including the risks of expropriation and renegotiation of the terms of contracts with governmental entities, delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics, regional conflicts, such as the Russia-Ukraine war and the conflict in the Middle East, and a significant cyber security, data privacy, or IT incident; (n) the pace of the energy transition; and (o) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plc's Form 20-F and amendment thereto for the year ended December 31, 2024 (available at and ). These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement, July 31, 2025. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. In light of these risks, results could differ materially from those stated, implied or inferred from the forward-looking statements contained in this announcement. Shell's net carbon intensity Also, in this announcement we may refer to Shell's 'net carbon intensity' (NCI), which includes Shell's carbon emissions from the production of our energy products, our suppliers' carbon emissions in supplying energy for that production and our customers' carbon emissions associated with their use of the energy products we sell. Shell's NCI also includes the emissions associated with the production and use of energy products produced by others which Shell purchases for resale. Shell only controls its own emissions. The use of the terms Shell's 'net carbon intensity' or NCI is for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries. Shell's net-zero emissions target Shell's operating plan and outlook are forecasted for a three-year period and ten-year period, respectively, and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next three and ten years. Accordingly, the outlook reflects our Scope 1, Scope 2 and NCI targets over the next ten years. However, Shell's operating plan and outlook cannot reflect our 2050 net-zero emissions target, as this target is outside our planning period. Such future operating plans and outlooks could include changes to our portfolio, efficiency improvements and the use of carbon capture and storage and carbon credits. In the future, as society moves towards net-zero emissions, we expect Shell's operating plans and outlooks to reflect this movement. However, if society is not net zero in 2050, as of today, there would be significant risk that Shell may not meet this target. Forward-Looking non-GAAP measures This announcement may contain certain forward-looking non-GAAP measures such as adjusted earnings and divestments. We are unable to provide a reconciliation of these forward-looking non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell, such as oil and gas prices, interest rates and exchange rates. Moreover, estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plc's consolidated financial statements. The contents of websites referred to in this announcement do not form part of this announcement. We may have used certain terms, such as resources, in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F and any amendment thereto, File No 1-32575, available on the SEC website . LEI number of Shell plc: 21380068P1DRHMJ8KU70 Classification: Additional regulated information required to be disclosed under the laws of the United Kingdom
Business Upturn
6 days ago
- Business Upturn
Can-Fite Announces Up To $15.0 Million Public Offering
$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) ('Can-Fite' or the 'Company'), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced the pricing of a public offering with a single institutional investor of 8,333,333 of the Company's American Depositary Shares ('ADSs') (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 16,666,666 ADSs at a combined public offering price of $0.60 per ADS (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants will have an exercise price of $0.60 per ADS, are exercisable upon issuance and will expire twenty-four months following the date of issuance. The offering is expected to close on or about July 29, 2025, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $5.0 million. The potential additional gross proceeds to the Company from the short-term warrants, if fully-exercised on a cash basis, will be approximately $10.0 million. No assurance can be given that any of such short-term warrants will be exercised. Can-Fite intends to use the net proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes. The securities described above are being offered and sold by Can-Fite pursuant to a registration statement on Form F-1 (File No. 333-288890), which was declared effective by the U.S. Securities and Exchange Commission (the 'SEC') on July 28, 2025. The offering is being made only by means of a prospectus forming a part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus may be obtained, when available, on the SEC's website at or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected]. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are 'forward looking statements'. Forward-looking statements can be identified by the use of forward-looking words such as 'believe,' 'expect,' 'intend,' 'plan,' 'may,' 'should' or 'anticipate' or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds therefrom and the exercise of the short-term warrants prior to their expiration. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the 'Risk Factors' section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. ContactCan-Fite BioPharmaMotti Farbstein [email protected]
